There are currently 62 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and Ontario.
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
NCT06345404
Recruiting
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Corvus Clinical Trials Information, Burlingame, California
Conditions: Atopic Dermatitis
Register for Updates
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT00605878
Recruiting
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema. Healthy volunteers, as well as patients with moderate to severe eczema (AD), between 2 and 40 years of age may be eligible for this study. We also wish to enroll children and adults aged 2-40 who... Read More
Gender:
All
Ages:
Between 2 years and 100 years
Trial Updated:
03/28/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema, Ichthyosis Vulgaris
Register for Updates
Bone Health in Patients With Atopic Dermatitis
NCT03800004
Recruiting
This study examines the bone health in children with atopic dermatitis
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
03/27/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
NCT04864886
Recruiting
Background: The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal. Researchers want to learn more to better treat conditions that affect immune response. Objective: To learn about how the immune system and skin healing are related to each other. Eligibility: People ages 18-75 with primary immune deficiency, eczema, or psoriasis. Health... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Primary Immunodeficiency, Psoriasis, Atopic Dermatitis, Immune-mediated Diseases
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
03/27/2024
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +332 locations
Conditions: Atopic Dermatitis
Register for Updates
Study of Skin Microbiome in AD and PS Patients
NCT04170244
Recruiting
Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis [AD]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria plays in psoriasis (i.e. disease severity, biomarkers and skin barrier function). The overarching purpose of this longitudinal study is to understand how the abundance of skin S. aureus (and several com... Read More
Gender:
All
Ages:
13 years and above
Trial Updated:
03/22/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atopic Dermatitis, Psoriasis
Register for Updates
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156
Recruiting
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 3-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic therapy. Participants will be randomized to receive SAR444656 dose 1, SAR444656 dose 2 or matching placebo. Participants who meet inclusion/exclusion criteria will be stratified for randomization by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Clear Dermatology & Aesthetics Center Site Number: 8400003, Scottsdale, Arizona +15 locations
Conditions: Atopic Dermatitis
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
03/19/2024
Locations: Clear Dermatology & Aesthetics Center/Investigative MD, Scottsdale, Arizona +62 locations
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
Dupixent and Narrowband UVB for Atopic Dermatitis
NCT05285839
Recruiting
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Eczema Treatment Center of New Jersey, East Windsor, New Jersey
Conditions: Atopic Dermatitis
Register for Updates
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT05696392
Recruiting
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: First Oc Dermatology, Fountain Valley, California +29 locations
Conditions: Atopic Dermatitis
Register for Updates
Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
NCT01782703
Recruiting
Atopic dermatitis (AD), also known as eczema, is the most common inflammatory skin disorder of children, affecting 10-20% of children and 1-2% of adults. This skin disorder can be associated with unbearable itchiness and an increased susceptibility to skin infections. The cause of AD is currently poorly understood; therefore, there are no targeted treatment options at present. There have been recent studies in adults with AD that explain the cause and give us new routes to investigate treatment... Read More
Gender:
All
Ages:
Between 0 months and 17 years
Trial Updated:
03/11/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois +3 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
NCT05859724
Recruiting
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/09/2024
Locations: First OC Dermatology Research, Fountain Valley, California +21 locations
Conditions: Atopic Dermatitis
Register for Updates